Introduction
============

Gastric cancer is one of the most common human epithelial malignancies and remains the second leading cause of cancer-associated mortality for clinical cancer ([@b1-etm-0-0-5388]). Clinical statistics and investigations have shown that \>70% of new cases of gastric cancer-associated deaths occur in developing countries ([@b2-etm-0-0-5388],[@b3-etm-0-0-5388]). Gastric cancer exhibits higher morbidity and mortality rates than other carcinoma derived from the digestive system as gastric cancer is more invasive ([@b4-etm-0-0-5388],[@b5-etm-0-0-5388]). A previous study has indicated that the five-year survival rate for gastric cancer is \<80% ([@b6-etm-0-0-5388]).

Currently, the majority of clinical patients with gastric cancer are categorized as having an advanced stage once diagnosed. In addition, although reports have shown that apoptosis-resistance of gastric cancer is inevitable in the development of cancer progression, the apoptotic resistance of gastric cancer cells in patients with gastric cancer has been indicated as the most important hurdle to overcome in clinical treatment ([@b7-etm-0-0-5388],[@b8-etm-0-0-5388]). Furthermore, apoptotic resistance has become the greatest challenge in cancer therapy due to fierce resistance of tumor cells though various types of molecules mechanism ([@b9-etm-0-0-5388]--[@b11-etm-0-0-5388]). Although several comprehensive therapies exist that induce apoptosis, which is the most important component of treatment for patients with gastric cancer, the survival rate remains low ([@b12-etm-0-0-5388]). These previous reports focused on the efficacy of targeted molecular therapies, and the early diagnosis of gastric cancer is often overlooked.

In recent years, contrast-enhanced ultrasound, computed tomography, fl tomography, ont-positron emission, and tomography (FDG-PET) has been widely used in the diagnosis of human cancer ([@b13-etm-0-0-5388]). Although many advantages of contrast-enhanced ultrasound have been presented, its relatively reduced resolution compared with CT means that it cannot confirm the final diagnosis for patients with suspected gastric cancer ([@b14-etm-0-0-5388]). However, nanoscale microbubbles have been used to improve the resolution of ultrasound, as they resonate when exposed to ultrasound waves ([@b14-etm-0-0-5388],[@b15-etm-0-0-5388]). In addition, computerized tomography and chip technology are the most common methods used to diagnose patients with suspected cancer ([@b16-etm-0-0-5388]). However, the efficacy of single computerized tomography is limited to diagnosing patients with early phase tumors. Furthermore, contrast agent combined with CT for the analysis of tumor biology has been studied and achieved adequate efficacy ([@b17-etm-0-0-5388]). Therefore, we hypothesized that specific-targeted nanoscale microbubbles may contribute to the efficacy and resolution of CT in the diagnosis of patients with suspected gastric cancer.

In the present study, CECT combined with targeting nanoscale microbubble contrast agent (CECT-TNCA) was introduced to detect the early stage of patients with suspected gastric cancer. Notably, CECT in conjunction with ultrasound contrast further expanded its application in the field of primary diagnosis and confirmed diagnosis ([@b18-etm-0-0-5388]). This clinical analysis demonstrated the potential application of CECT-TNCA for imaging modality and sensitivity improvements in the diagnosis of gastric cancer. Our outcomes indicated many advantages of CECT-TNCA in both early diagnosis and final confirmation of suspected cases when compared to single CT detection.

Materials and methods
=====================

### Ethics statement

The design of this clinical study was carried out in strict accordance with the approval and recommendations in the Guide for the Care and Use of clinical study of Xianning Central Hospital (XNCH: 20091108A4). All surgery and euthanasia protocols were standardized. All patients provided written informed consent.

### Patients

A total of 484 patients with suspected gastric cancer aged 14.8--65.2 years were recruited for this prospective analysis, in which the follow-up period was 60 months. The number of male (222) and female (264) patients was approximately equal. Furthermore, 236 healthy subjects (male, 124; female, 112) aged 24.0--62.6 years were recruited. Biochemical parameters of patients with suspected NSCLC and healthy subjects recruited between May 2012 and June 2015 were eligible for further analysis. All patients were subjected to scanning for the detection of early-stage gastric cancer by CECT and CECT-TNCA. All healthy subjects had no cancer history or gastric diseases. Patients with cancer history were excluded in the present study.

### Nanoparticles contrast agent

A novel liposome-encapsulated nanoparticles contrast agent containing multiple targets was introduced for diagnosing patients with early-stage gastric cancer. Platelet-derived growth factor receptor-β (PDGFR-β), Ret, and Kit bound with the nanoparticles of superparamagnetic iron oxide particles via covalent bonds described in a previous study ([@b19-etm-0-0-5388]). Nanoparticles contrast agent and Optison (GE Healthcare, Chicago, IL, USA) were orally administered to ensure that they covered each corner of the stomach prior to CECT and CECT-TNCA (30 min). Following administration with CECT-TNCA, the TNCA was distributed in the stomach. Microbubbles contained targeting nanoparticles contrast agent with the capacity to target travelling tumor cells, which acted as an accurate tracer for tumor cells ([@b20-etm-0-0-5388]). TNCA was located in the lesion following administration with CECT-TNCA. After 30 min, the TNCA was visualized via CECT. No side effects were observed in patients exposed to TNCA.

### Scan protocol

A CECT diagnosis system was used to analyze CECT clinical trials using preprogrammed settings. Preprogrammed settings were optimized to achieve optimal image formation. CECT was performed on the stomachs of all patients according to manufacturers instructions (Philips Medical Systems, Inc., Bothell, WA, USA). Details of the principles and settings of contrast-enhanced ultrasound were described in a previous study ([@b21-etm-0-0-5388]). In addition, CECT-TNCA imaging was performed in all patients with suspected gastric cancer.

### Data analysis

Data from CECT-TNCA image sets was analyzed using the ADMIRE CECT system (version 3.10; Siemens Healthineers, Erlangen, Germany). Volume of tumors was measured by CECT-TNCA imaging. All patients with suspected early stage gastric cancer were analyzed by CECT-TNCA and CT. Gastric tumor nodules were observed and tumor size was automatically calculated using Sante CT Viewer (version 2.0; Santesoft, Ltd., Athens, Greece).

### Treatment of patients with gastric cancer diagnosed by CECT-TNCA

Patients with early stage gastric cancer diagnosed by CECT-TNCA received various different treatments including radiotherapy (n=39), chemotherapy (n=49), Chinese medicine (n=58), biological therapy (n=35), and comprehensive therapy (n=53). Median overall survival and median progression-free survival were analyzed as previously described ([@b22-etm-0-0-5388]).

### Immunofluorescence and histological staining

Following diagnostic confirmation via CECT-TNCA, tumor cells from patients with gastric cancer were cultured *in vitro* with Dulbecco\'s modified Eagle\'s medium supplemented with 10% heat-inactivated FBS (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Gastric tumors cells (1×10^6^ cells/ml) were incubated with TNCA for 30 min at 37°C. Cells were observed under a fluorescence microscope. Immunofluorescence procedures were previously reported in detail ([@b23-etm-0-0-5388]). For histological staining, tumor sections were stained with hematoxylin and eosin staining as previously reported ([@b24-etm-0-0-5388]).

### Statistical analysis

All data were presented as the mean and standard deviation of triplicate experiments. Unpaired data was determined by Student\'s t-test and comparisons of data between multiple groups were analyzed by variance. Kaplan-Meier was used to estimate the survival rate during 60-month long-term follow-up observations. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Plasma concentrations of PDGFR-β, Ret, and Kit in patients with suspected gastric cancer

In order to analyze the target characteristic of TNCA, a total of 484 patients with suspected gastric cancer were voluntarily recruited to investigate the efficacy of CECT-TNCA in the diagnosis of patients with early-stage gastric cancer. Characteristics of patients with suspected gastric cancer are summarized in [Table I](#tI-etm-0-0-5388){ref-type="table"}. The dose of TNCA to achieve the optimum efficiency was identified as 15 mg/kg ([Table II](#tII-etm-0-0-5388){ref-type="table"}). In addition, we investigated the plasma concentration of PDGFR-β, Ret, and Kit in patients with suspected gastric cancer. As shown in [Fig. 1A](#f1-etm-0-0-5388){ref-type="fig"}, PDGFR-β plasma concentration was significantly lower in patients with gastric cancer when compared with healthy subjects. We also found that plasma concentration of Ret was significantly downregulated in patients with gastric cancer when compared with healthy subjects ([Fig. 1B](#f1-etm-0-0-5388){ref-type="fig"}). In addition, compared with healthy subjects, plasma concentration of Kit was significantly lower in patients with gastric cancer ([Fig. 1C](#f1-etm-0-0-5388){ref-type="fig"}). Furthermore, clinical analysis also indicated that our novel TNCA containing PDGFR-β, Ret, and Kit adhered to gastric cancer cells, which contributed to the signal strength and resolution ([Fig. 2](#f2-etm-0-0-5388){ref-type="fig"}).

### Efficacy of CECT-TNCA for the early diagnosis of patients with suspected gastric cancer

As shown in [Fig. 3](#f3-etm-0-0-5388){ref-type="fig"}, clinical analysis showed that 182 patients (37.6%) were diagnosed as tumor-free and 302 patients (62.4%) were identified as having gastric cancer, as determined by CECT-TNCA. However, the positive rate of patients with gastric cancer was only 22.3% (108 patients) when evaluated via CECT alone. In addition, the investigation found that TNCA increased the plasma concentration of PDGFR-β and metabolized within 24 h ([Fig. 4A](#f4-etm-0-0-5388){ref-type="fig"}). Patients who underwent CECT-TNCA exhibited increasing plasma concentrations of Ret that peaked at 12 h and attenuated by 16 h ([Fig. 4B](#f4-etm-0-0-5388){ref-type="fig"}). Plasma concentrations of Kit were increased and metabolized within 20 h ([Fig. 4C](#f4-etm-0-0-5388){ref-type="fig"}). These clinical data indicated that CECT-TNCA is an efficient diagnostic strategy for the early diagnosis of patients with suspected gastric cancer.

Histopathology analysis of the accuracy of CECT-TNCA-diagnosis patients with gastric cancer. After diagnosing patients with suspected gastric cancer, histopathology analysis was used to further confirm diagnosis. Representative cardiac carcinoma, gastric cancer and pylorus carcinoma incidence rates were studied in the patients who had a confirmed diagnosis of gastric cancer. As shown in [Fig. 5](#f5-etm-0-0-5388){ref-type="fig"}, our data showed that histopathology analysis identified cardiac carcinoma, gastric cancer and pyloric carcinoma gastric cancer. The incidence rate of cardiac carcinoma, gastric cancer and pyloric carcinoma was 33.8% (102 cases), 47.0% (142 cases) and 19.2% (58 cases), respectively, in gastric cancer ([Fig. 6](#f6-etm-0-0-5388){ref-type="fig"}). These outcomes suggest that the CECT-TNCA method is accurate and sensitive for diagnosing patients with gastric cancer.

### Survival rate of patients with gastric cancer diagnosed by CECT-TNCA

Patients with early-phase gastric cancer received different treatments to inhibit tumor cell growth or eradicate gastric cancer. We analyzed the reports of the treatment methods and survival rates of patients with gastric cancer diagnosed by CECT-TNCA. Characteristics of 234 patients with early-phase gastric cancer diagnosed by CECT-TNCA are summarized in [Table III](#tIII-etm-0-0-5388){ref-type="table"}. At the 60-month follow-up, we observed that 132 patients (56.4%) were tumor-free and 88 patients (37.6%) had survived and exhibited tumors. The mortality rate was 6.0% (14 patients; [Table IV](#tIV-etm-0-0-5388){ref-type="table"}). Median overall survival was 45.8 months ([Fig. 7](#f7-etm-0-0-5388){ref-type="fig"}; range, 30.4--63.8 months) and median progression-free survival was 36.8 months ([Fig. 8](#f8-etm-0-0-5388){ref-type="fig"}; range, 24.5--52.4 months). These data indicate that patients with early-phase gastric cancer received anti-cancer treatments that prolonged the survival and progression-free survival period, and that that comprehensive therapy had notable therapeutic effects compared with the others treatments.

Discussion
==========

Cancer early diagnosis is the biggest obstacle in human cancer treatment ([@b25-etm-0-0-5388],[@b26-etm-0-0-5388]). In recent years, contrast-enhanced ultrasound, fluorodeoxyglucose-positron emission, tomography (FDG-PET), CECT and chip technology have been widely used in the diagnosis of human cancer ([@b27-etm-0-0-5388],[@b28-etm-0-0-5388]). In particular, CECT and chip technology present more advantages than other diagnostic methods ([@b29-etm-0-0-5388],[@b30-etm-0-0-5388]). However, the application of gene chip technology is restricted due to expensive detection and the professional analysts required ([@b31-etm-0-0-5388],[@b32-etm-0-0-5388]). Therefore, CECT has been become the most prevalent diagnostic method in the majority of hospitals worldwide ([@b33-etm-0-0-5388],[@b34-etm-0-0-5388]).

Though CECT has been widely applied in the diagnosis of human cancer, the accuracy and sensitivity of CECT is insufficient for the detection of early-stage tumors ([@b35-etm-0-0-5388],[@b36-etm-0-0-5388]). Barium sulfate and iodinated contrast media are frequently used for angiography studies and the diagnosis of tumors in the digestive system ([@b37-etm-0-0-5388],[@b38-etm-0-0-5388]). In addition, many electropositive iron and iron oxide nanoparticles are used as contrast media and have been reported to be useful in the diagnosis of human cancer in previous clinical trials ([@b39-etm-0-0-5388],[@b40-etm-0-0-5388]). Furthermore, retroreflective-type Janus microspheres have also been reported as a novel contrast agent for enhanced optical coherence tomography ([@b41-etm-0-0-5388]). However, these contrast mediums only improve the partial accuracy of CT in a certain degree. Therefore, elucidating more efficient contrast mediums with targeting characteristics has attracted increasing attention from researchers and clinicians in the field of cancer research and clinical therapy.

In the present study, we introduced a comprehensive approach of CECT combined with target nanoparticles contrast agent to improve the accuracy for patients with suspected gastric cancer in the early stage. Target nanoparticles contrast mediums, containing PDGFR-β, Ret, and Kit, were encapsulated by liposome. Our clinical outcomes indicate that liposome-encapsulated TNCA presents a potential tumor-specific approach that may lead to improvements in the diagnostic accuracy of patients with early-stage gastric cancer. Targeted binding of liposome-encapsulated TNCA with gastric tumor cells enhances signal intensity in the lesions of the stomach, resulting in an improvement in the spatial resolution of CECT. Notably, pharmacokinetic tracer kinetics analysis demonstrated that the target nanoparticles contrast mediums of PDGFR-β, Ret, and Kit were metabolized within 24 h. No side effects were noted during the diagnostic period. Long-term follow-up reports showed that patients diagnosed by CECT-TNCA at the early stage present higher median overall survival (30.4--63.8 months) and median progression-free survival (24.5--52.4 months).

Tyrosine kinase inhibitors of PDGFR-β, Ret, and Kit-mediated angiogenesis have been identified as key factors in the development of human cancer ([@b42-etm-0-0-5388],[@b43-etm-0-0-5388]). PDGFR-β, Ret, and Kit have potent anti-tumor activity against a number of human tumors through binding with targets ([@b44-etm-0-0-5388]). Previous reports have suggested that target receptors of PDGFR-β, Ret, and Kit in gastric tumors are effective treatments ([@b45-etm-0-0-5388]--[@b47-etm-0-0-5388]). Although previous contrast media have not previously been compared to determine which media is optimal for the visualization and diagnosis of gastric cancer ([@b48-etm-0-0-5388]). Indeed, CECT using a different contrast agent enables non-destructive diagnosis of the biochemical and biomechanical properties of patients with various diseases ([@b49-etm-0-0-5388]). In addition, a previous study has evaluated dynamic CECT imaging in the differentiation of benign and malignant tumors observed by tumor vessel and permeability nodule perfusion ([@b50-etm-0-0-5388]). However, conventional contrast agents present lower efficacy for tumor analysis due to rapid diffusion outside the lungs, which prevents optimal imaging ([@b51-etm-0-0-5388]). Furthermore, previous reports have shown that iodinated contrast agents are less sensitive to changes in cells morphology ([@b52-etm-0-0-5388],[@b53-etm-0-0-5388]). Our design showed that liposome-encapsulated target nanoparticles contrast mediums are potential nanoparticles contrast agents that may improve the accuracy of diagnosing early-stage gastric tumors. Targeted binding of target nanoparticles contrast mediums with gastric tumor cells enhanced signal intensity in lesions in stomachs diagnosed by CECT-TNCA.

In conclusion, to the best of our knowledge, this is the first report of liposome-encapsulated targeted nanoparticles contrast mediums combined with CECT for the diagnosis of patients with suspected early stage gastric cancer. CECT-TNCA was administered orally to augment the signal intensity in the stomach, leading to a reliable and sensitive assessment of the tumor for clinical diagnosis in patients with gastric cancer.

![Analysis of plasma concentrations of (A) PDGFR-β, (B) Ret and (C) Kit between patients with gastric cancer and healthy subjects. \*\*P\<0.01 vs. control (Student\'s t-test). PDGFR-β, platelet-derived growth factor receptor-β.](etm-15-01-0047-g00){#f1-etm-0-0-5388}

![Immunostaining assay of PDGFR-β, Ret and Kit for gastric cancer cells from patients with gastric cancer. PDGFR-β, platelet-derived growth factor receptor-β (magnification, ×40).](etm-15-01-0047-g01){#f2-etm-0-0-5388}

![Comparison of the confirmed diagnosis rate determined by CECT and CECT-TNCA. \*\*P\<0.01 vs. control (Student\'s t-test). CECT-TNCA, contrast-enhanced computed tomography-targeting nanoparticles contrast agent.](etm-15-01-0047-g02){#f3-etm-0-0-5388}

![Metabolism of (A) PDGFR-β, (B) Ret and (C) Kit in targeting nanoparticles contrast agent in serum in patients who underwent CECT-TNCA. CECT-TNCA, contrast-enhanced computed tomography-targeting nanoparticles contrast agent.](etm-15-01-0047-g03){#f4-etm-0-0-5388}

![Histological staining analyses the types of gastric cancers in patients diagnosed by CECT-TNCA. CECT-TNCA, contrast-enhanced computed tomography-targeting nanoparticles contrast agent (magnification, ×40).](etm-15-01-0047-g04){#f5-etm-0-0-5388}

![Analysis the incidence rate of the types of gastric cancers in patients diagnosed by CECT-TNCA. One-way analysis of variance revealed a significant effect. \*\*P\<0.01 vs. control. CECT-TNCA, contrast-enhanced computed tomography-targeting nanoparticles contrast agent.](etm-15-01-0047-g05){#f6-etm-0-0-5388}

![Evaluation the median overall survival of patients diagnosed by CECT-TNCA in early stage. Kaplan-Meier was used to estimate the survival rate during 60-months long-term observation. CECT-TNCA, contrast-enhanced computed tomography-targeting nanoparticles contrast agent.](etm-15-01-0047-g06){#f7-etm-0-0-5388}

![Analysis of the median progression-free survival of patients diagnosed by CECT-TNCA in early stage. Kaplan-Meier was used to estimate the survival rate during 60-months long-term observation. CECT-TNCA, contrast-enhanced computed tomography-targeting nanoparticles contrast agent.](etm-15-01-0047-g07){#f8-etm-0-0-5388}

###### 

Characteristics of patients with suspected gastric cancer.

  Characteristics                 Male         Female
  ------------------------------- ------------ ------------
  Patients (n)                    222          264
  Age (years)                     14.8--65.2   21.6--62.2
  Medical history of cancer (n)   3            5
  Blood pressure (mmHg)           110.2±12.8   113.4±10.3
  Blood glucose (mmol/l)          7.7±3.6      8.2±3.2
  Diagnosis (n)                                
    CECT-TNCA                     222          264
    CECT                          222          264

CECT-TNCA, contrast-enhanced computed tomography-targeting nanoparticles contrast agent.

###### 

Confirmation of the dosage of targeting nanoparticles contrast agent required for diagnosis.

  Variable                1--10mg/kg (n=16)   11--20mg/kg (n=24)   21--30mg/kg (n=20)
  ----------------------- ------------------- -------------------- --------------------
  Signal intensity (HU)   76.5±7.2            92.5±5.8             93.4±6.4
  Sensitive (%)           64.4±17.3           86.3±10.4            83.8±9.5

###### 

Treatment of patients with gastric cancer diagnosed by CECT-TNCA.

  Characteristics                 Male         Female
  ------------------------------- ------------ ------------
  Patients (n)                    114          120
  Age (years)                     15.6--56.2   22.4--52.8
  Medical history of cancer (n)   2            2
  Blood pressure (mm Hg)          108.6±8.5    107.5±9.8
  Blood glucose (mmol/l)            8.4±1.5      7.6±2.4
  Treatments (n)                               
  Radiotherapy                    18           21
  Chemotherapy                    25           24
  Chinese medicine                32           26
  Biological therapy              18           17
  Comprehensive therapy           21           32

CECT-TNCA, contrast-enhanced computed tomography-targeting nanoparticles contrast agent.

###### 

Survival of patients diagnosed by CECT-TNCA after 60-month follow-up.

  Treatment               Tumor-free   Survived with tumor(s)   DNS
  ----------------------- ------------ ------------------------ -----
  Radiotherapy            12           22                       5
  Chemotherapy            25           20                       4
  Chinese medicine        37           18                       3
  Biological therapy      19           15                       1
  Comprehensive therapy   39           13                       1

CECT-TNCA, contrast-enhanced computed tomography-targeting nanoparticles contrast agent; DNS, did not survive.
